$252 Million is the total value of CHI Advisors LLC's 28 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 55.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Buy | ORCHARD THERAPEUTICS PLCspon ads new | $14,034,773 | +256.4% | 12,315,654 | +1529.6% | 5.56% | +365.5% | |
| KROS | Buy | KEROS THERAPEUTICS INC | $12,995,340 | -19.6% | 407,633 | +1.4% | 5.15% | +5.1% |
| IKNA | Buy | IKENA ONCOLOGY INC | $9,443,445 | -32.2% | 2,180,934 | +2.8% | 3.74% | -11.4% |
| RARE | Buy | ULTRAGENYX PHARMACEUTICAL IN | $7,664,750 | +95.5% | 215,000 | +152.9% | 3.04% | +155.3% |
| New | MINERALYS THERAPEUTICS INC | $5,405,284 | – | 568,379 | +100.0% | 2.14% | – | |
| INZY | Buy | INOZYME PHARMA INC | $5,334,112 | -19.9% | 1,270,027 | +6.3% | 2.11% | +4.7% |
| Buy | SYROS PHARMACEUTICALS INC | $5,119,170 | +111.8% | 1,299,359 | +69.3% | 2.03% | +176.4% | |
| BPMC | New | BLUEPRINT MEDICINES CORP | $4,664,835 | – | 92,888 | +100.0% | 1.85% | – |
| Buy | 2SEVENTY BIO INC | $3,927,867 | -54.4% | 1,002,007 | +17.6% | 1.56% | -40.5% | |
| New | MOONLAKE IMMUNOTHERAPEUTICSclass a ord | $3,420,000 | – | 60,000 | +100.0% | 1.36% | – | |
| New | SAGIMET BIOSCIENCES INC | $3,069,810 | – | 348,842 | +100.0% | 1.22% | – | |
| Buy | FREELINE THERAPEUTICS HLDGSsponsored ads | $372,613 | +566.6% | 86,654 | +300.0% | 0.15% | +770.6% | |
| RPTX | New | REPARE THERAPEUTICS INCcall | $157,500 | – | 50,000 | +100.0% | 0.06% | – |
| PLRX | Buy | PLIANT THERAPEUTICS INCcall | $55,000 | -66.0% | 137,500 | +5.5% | 0.02% | -55.1% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PRECISION BIOSCIENCES INC | 17 | Q3 2023 | 13.4% |
| OVID THERAPEUTICS INC | 17 | Q3 2023 | 5.8% |
| CORVUS PHARMACEUTICALS INC | 16 | Q2 2023 | 1.8% |
| KEZAR LIFE SCIENCES INC | 15 | Q1 2023 | 5.8% |
| PLIANT THERAPEUTICS INC | 14 | Q3 2023 | 29.2% |
| REPARE THERAPEUTICS INC | 14 | Q3 2023 | 30.3% |
| ORCHARD THERAPEUTICS PLC | 14 | Q4 2022 | 52.6% |
| LARIMAR THERAPEUTICS INC | 14 | Q3 2023 | 9.1% |
| KEROS THERAPEUTICS INC | 14 | Q3 2023 | 8.6% |
| INOZYME PHARMA INC | 13 | Q3 2023 | 9.4% |
View CHI Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc. | February 13, 2023 | 2,384,402 | 5.1% |
| Cullinan Oncology, Inc. | February 13, 2023 | 3,317,544 | 7.2% |
| Freeline Therapeutics Holdings plc | February 13, 2023 | 4,814,419 | 7.4% |
| Inozyme Pharma, Inc. | February 13, 2023 | 2,204,876 | 5.5% |
| Larimar Therapeutics, Inc. | February 13, 2023 | 3,473,366 | 8.0% |
| Oncorus, Inc. | February 13, 2023 | 2,367,436 | 9.1% |
| Orchard Therapeutics plc | February 13, 2023 | 7,987,396 | 6.3% |
| PLIANT THERAPEUTICS, INC. | February 13, 2023 | 3,199,892 | 6.6% |
| Repare Therapeutics Inc. | February 13, 2023 | 2,800,126 | 6.7% |
| VectivBio Holding AG | February 13, 2023 | 5,492,893 | 8.8% |
View CHI Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-13 |
| 13F-HR/A | 2023-08-22 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-11 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
View CHI Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.